NMLSFOTCHealthcare · Biotechnology

Restart Life Sciences Corp.

$0.06-12.77%($-0.01)

TickerSpark Score

44/100

Weak

Valuation

Profitability

Growth

Health

Momentum

Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NMLSF research report →

52-Week Range33% of range

Low $0.04

Current $0.06

High $0.12

Companywww.restartlife.co

Restart Life Sciences Corp. is a biotechnology company, which engages in the research and development of psilocybin. It offers therapy and diagnostics for neuroinflammatory disorders.

CEO: Steve Loutskou
IPO: 2008
HQ: Vancouver, BC, CA

Price Chart

-50.20% · this period

Valuation

Market Cap: $2.37M
P/E: -2.32
P/S: 0.00
P/B: 2.50
EV/EBITDA: -1.58
Div Yield: 0.00%

Profitability

Gross Margin: 0.00%
Op Margin: 0.00%
Net Margin: 0.00%
ROE: -379.02%
ROIC: -87.79%

Growth & Income

Revenue: $0 · 0.00%
Net Income: $-1,390,538 · -718.72%
EPS: $-0.00 · -102.72%
Op Income: $-1,345,316
FCF YoY: -899.29%

Performance & Tape

52W High: $0.12
52W Low: $0.04
50D MA: $0.08
200D MA: $0.07
Beta: -0.87
Avg Volume: 10.83K

Get TickerSpark's AI analysis on NMLSF

Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

30-day money-back guarantee · cancel anytime